# Efficacy and Safety of Xinyue Capsule in the Treatment of Heart Failure With Preserved Ejection Fraction

Study · id `cardio:ct-nct06946095` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06946095](<https://clinicaltrials.gov/study/NCT06946095>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06946095

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 246 participants.

## Technical summary

Registry record NCT06946095. Randomized; no masking; primary purpose treatment. Start 2025-05-20 (anticipated); primary completion 2027-10-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 246 participants (planned count; ClinicalTrials.gov record NCT06946095, source copy `cardio:ctgov-nct06946095-2025-04-27`, retrieved 2026-10-26)
- Planned start: 2025-05-20 (anticipated) (ClinicalTrials.gov record NCT06946095, source copy `cardio:ctgov-nct06946095-2025-04-27`, retrieved 2026-10-26)
- Primary completion: 2027-10-31 (anticipated) (ClinicalTrials.gov record NCT06946095, source copy `cardio:ctgov-nct06946095-2025-04-27`, retrieved 2026-10-26)
- Completion: 2027-10-31 (anticipated) (ClinicalTrials.gov record NCT06946095, source copy `cardio:ctgov-nct06946095-2025-04-27`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06946095-2025-04-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Xinyue Capsule in the Treatment of Heart Failure With Preserved Ejection Fraction
- Condition: Heart Failure
- Intervention (Drug): Chinese patent medicine
- Lead sponsor: Beijing Anzhen Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: Beijing Anzhen Hospital (`cardio:org-beijing-anzhen-hospital`)

## Provenance

Content hash: fa73bbe66c753baf4a53f0107bb96aa99e7306d6954f3af7344c0779d66891a2
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
